Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Large Decline in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 120,590 shares, a drop of 46.1% from the November 30th total of 223,895 shares. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days.

Liminatus Pharma Price Performance

Liminatus Pharma stock traded down $0.06 during trading on Friday, hitting $0.65. The company’s stock had a trading volume of 184,407 shares, compared to its average volume of 126,256. The stock has a fifty day moving average price of $1.02. Liminatus Pharma has a 1-year low of $0.61 and a 1-year high of $33.66. The stock has a market capitalization of $17.52 million and a PE ratio of -5.39.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LIMN shares. Wall Street Zen downgraded shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.